Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Platinum-based chemotherapeutic agents exert their antitumor effects primarily through the formation of covalent adducts with DNA, causing intra- and interstrand crosslinks that block DNA replication and transcription. This indirect enzyme inhibition results from physical and chemical distortion of the DNA template, which impedes the function of replication and transcription machinery, ultimately leading to cell cycle arrest and apoptosis in cancer cells. These drugs are widely used in the treatment of various solid tumors but are limited by resistance mechanisms and notable toxicities[2][3][5][6].
Formation of platinum–DNA adducts that block DNA replication and transcription machinery; Induction of DNA crosslinks leading to cell cycle arrest and apoptosis; Recruitment/hijacking of transcription factors to damaged DNA.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA (primary target of platinum agents via adduct formation).